Nifty
Sensex
:
:
14433.70
49034.67
-161.90 (-1.11%)
-549.49 (-1.11%)

Pharmaceuticals & Drugs - Global

Rating :
63/99  (View)

BSE: 532523 | NSE: BIOCON

457.05
-9.40 (-2.02%)
15-Jan-2021 | 4:01PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  466.50
  •  466.60
  •  455.00
  •  466.45
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2795557
  •  12777.09
  •  487.75
  •  235.55

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 54,810.00
  • 85.05
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 56,472.80
  • N/A
  • 7.78

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.67%
  • 0.91%
  • 10.59%
  • FII
  • DII
  • Others
  • 17.65%
  • 6.00%
  • 4.18%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.43
  • 13.72
  • 15.58

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -5.97
  • 10.36
  • 8.68

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.78
  • 8.01
  • 30.32

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 24.78
  • 41.63
  • 55.66

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.41
  • 5.50
  • 6.38

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 19.49
  • 24.56
  • 28.22

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Net Sales
1,744.80
1,567.30
11.33%
1,671.30
1,458.90
14.56%
1,581.00
1,528.80
3.41%
1,748.10
1,540.80
13.45%
Expenses
1,353.40
1,164.50
16.22%
1,258.00
1,021.40
23.16%
1,262.40
1,125.80
12.13%
1,303.90
1,160.10
12.40%
EBITDA
391.40
402.80
-2.83%
413.30
437.50
-5.53%
318.60
403.00
-20.94%
444.20
380.70
16.68%
EBIDTM
22.43%
25.70%
24.73%
29.99%
14.01%
14.01%
25.41%
24.71%
Other Income
15.50
38.40
-59.64%
18.30
24.10
-24.07%
63.10
28.20
123.76%
35.80
25.60
39.84%
Interest
6.50
13.80
-52.90%
12.50
16.60
-24.70%
16.80
15.90
5.66%
17.70
18.60
-4.84%
Depreciation
177.70
131.60
35.03%
166.80
124.20
34.30%
152.40
119.80
27.21%
144.00
116.70
23.39%
PBT
222.70
363.30
-38.70%
252.30
320.80
-21.35%
212.50
295.50
-28.09%
318.30
276.80
14.99%
Tax
22.30
100.10
-77.72%
80.90
85.20
-5.05%
45.00
40.90
10.02%
84.80
46.10
83.95%
PAT
200.40
263.20
-23.86%
171.40
235.60
-27.25%
167.50
254.60
-34.21%
233.50
230.70
1.21%
PATM
11.49%
16.79%
10.26%
16.15%
7.11%
7.11%
13.36%
14.97%
EPS
1.41
1.80
-21.67%
1.25
1.72
-27.33%
28.29
28.29
0.00%
1.69
1.81
-6.63%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
6,745.20
6,367.20
5,514.40
4,123.40
3,891.10
3,347.40
3,089.80
2,877.30
2,485.30
2,086.50
1,806.00
Net Sales Growth
10.65%
15.46%
33.73%
5.97%
16.24%
8.34%
7.39%
15.77%
19.11%
15.53%
 
Cost Of Goods Sold
6,294.40
2,052.20
1,896.60
1,636.10
1,446.60
1,290.40
1,255.60
1,186.10
1,044.40
852.00
725.40
Gross Profit
450.80
4,315.00
3,617.80
2,487.30
2,444.50
2,057.00
1,834.20
1,691.20
1,440.90
1,234.50
1,080.60
GP Margin
6.68%
67.77%
65.61%
60.32%
62.82%
61.45%
59.36%
58.78%
57.98%
59.17%
59.83%
Total Expenditure
5,177.70
5,110.20
4,390.60
3,294.30
2,911.60
2,579.60
2,394.00
2,190.20
1,946.30
1,809.30
2,213.40
Power & Fuel Cost
-
246.10
239.80
189.00
156.40
184.70
176.70
162.40
142.60
97.20
82.00
% Of Sales
-
3.87%
4.35%
4.58%
4.02%
5.52%
5.72%
5.64%
5.74%
4.66%
4.54%
Employee Cost
-
1,458.80
1,165.30
931.10
747.00
610.10
533.40
466.30
389.40
307.60
238.80
% Of Sales
-
22.91%
21.13%
22.58%
19.20%
18.23%
17.26%
16.21%
15.67%
14.74%
13.22%
Manufacturing Exp.
-
864.60
721.20
335.70
391.50
203.70
81.20
62.90
95.20
113.20
81.60
% Of Sales
-
13.58%
13.08%
8.14%
10.06%
6.09%
2.63%
2.19%
3.83%
5.43%
4.52%
General & Admin Exp.
-
182.10
53.00
56.80
21.70
144.60
165.70
131.80
122.20
93.20
82.40
% Of Sales
-
2.86%
0.96%
1.38%
0.56%
4.32%
5.36%
4.58%
4.92%
4.47%
4.56%
Selling & Distn. Exp.
-
270.30
277.50
98.20
107.40
100.80
108.70
118.90
99.60
89.40
62.40
% Of Sales
-
4.25%
5.03%
2.38%
2.76%
3.01%
3.52%
4.13%
4.01%
4.28%
3.46%
Miscellaneous Exp.
-
36.10
37.20
47.40
41.00
45.30
72.70
61.80
52.90
256.70
62.40
% Of Sales
-
0.57%
0.67%
1.15%
1.05%
1.35%
2.35%
2.15%
2.13%
12.30%
52.09%
EBITDA
1,567.50
1,257.00
1,123.80
829.10
979.50
767.80
695.80
687.10
539.00
277.20
-407.40
EBITDA Margin
23.24%
19.74%
20.38%
20.11%
25.17%
22.94%
22.52%
23.88%
21.69%
13.29%
-22.56%
Other Income
132.70
507.50
414.30
206.20
157.10
79.20
53.10
55.90
56.70
309.40
1,035.50
Interest
53.50
64.90
70.90
61.50
26.00
29.30
8.90
1.70
8.10
12.40
24.30
Depreciation
640.90
552.20
447.80
385.10
277.20
248.70
221.00
203.60
179.30
175.80
156.70
PBT
1,005.80
1,147.40
1,019.40
588.70
833.40
569.00
519.00
537.70
408.30
398.40
447.10
Tax
233.00
315.10
212.30
156.90
161.60
142.20
95.70
106.90
97.50
55.90
72.10
Tax Rate
23.17%
25.94%
17.49%
26.65%
19.39%
19.49%
15.33%
19.88%
15.98%
14.03%
16.13%
PAT
772.80
777.10
904.40
351.10
595.80
528.70
497.40
413.80
508.90
341.60
367.50
PAT before Minority Interest
700.80
899.80
1,001.70
431.80
671.80
587.40
528.40
430.80
512.70
342.50
375.00
Minority Interest
-72.00
-122.70
-97.30
-80.70
-76.00
-58.70
-31.00
-17.00
-3.80
-0.90
-7.50
PAT Margin
11.46%
12.20%
16.40%
8.51%
15.31%
15.79%
16.10%
14.38%
20.48%
16.37%
20.35%
PAT Growth
-21.47%
-14.08%
157.59%
-41.07%
12.69%
6.29%
20.20%
-18.69%
48.98%
-7.05%
 
Unadjusted EPS
6.44
6.48
7.54
2.93
4.97
4.41
4.15
3.45
4.24
2.85
3.06

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
6,705.80
6,098.00
5,180.80
4,837.70
4,033.80
3,270.60
3,026.70
2,694.60
2,272.40
2,032.80
Share Capital
600.00
300.00
300.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
Total Reserves
5,997.00
5,720.80
4,812.30
4,670.20
3,933.80
3,132.70
2,806.20
2,491.80
2,079.80
1,850.50
Non-Current Liabilities
2,684.70
2,122.30
2,006.50
2,304.60
2,421.30
1,377.90
1,262.00
666.30
645.20
455.50
Secured Loans
1,220.80
1,523.50
1,787.00
2,104.30
2,061.00
758.20
580.40
124.00
9.30
0.00
Unsecured Loans
1.40
2.10
2.80
3.90
11.40
11.40
25.80
40.00
60.50
65.80
Long Term Provisions
85.80
66.10
49.30
36.00
29.90
15.00
7.80
4.00
0.00
1.00
Current Liabilities
4,008.00
3,038.50
2,141.30
1,678.30
1,665.70
1,554.70
1,379.60
989.90
1,015.80
1,060.60
Trade Payables
1,325.10
1,198.30
1,005.30
739.70
609.80
429.30
347.20
345.50
347.80
296.50
Other Current Liabilities
1,784.40
1,374.70
870.10
698.20
527.10
706.20
612.30
313.10
269.20
375.90
Short Term Borrowings
667.60
261.20
130.30
97.20
394.90
261.00
243.50
84.80
187.30
247.40
Short Term Provisions
230.90
204.30
135.60
143.20
133.90
158.20
176.60
246.50
211.50
140.80
Total Liabilities
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60
Net Block
5,971.10
4,471.00
3,699.50
3,625.10
1,748.30
1,629.90
1,525.20
1,510.30
1,270.50
1,316.20
Gross Block
9,147.40
7,095.00
5,873.80
5,436.10
3,403.60
3,034.20
2,701.70
2,480.90
2,066.20
1,965.80
Accumulated Depreciation
3,176.30
2,624.00
2,174.30
1,811.00
1,655.30
1,404.30
1,176.50
970.60
795.70
649.60
Non Current Assets
8,750.80
6,979.20
5,647.70
5,149.00
4,415.70
3,812.80
3,111.80
2,176.10
1,937.50
1,779.40
Capital Work in Progress
2,196.00
1,898.90
1,302.80
839.20
2,239.50
1,676.40
1,205.60
312.50
389.50
262.10
Non Current Investment
108.50
182.50
63.80
188.80
26.80
0.00
64.50
64.50
64.20
60.90
Long Term Loans & Adv.
402.00
335.80
437.20
319.70
350.10
336.90
252.00
241.60
181.00
140.20
Other Non Current Assets
73.20
91.00
144.40
176.20
51.00
169.60
64.50
47.20
32.30
0.00
Current Assets
5,325.00
4,888.50
4,148.60
4,047.70
3,970.90
2,562.60
2,638.80
2,240.00
1,999.70
1,807.20
Current Investments
857.60
829.30
611.40
1,065.00
874.70
230.30
700.40
522.10
492.10
399.50
Inventories
1,435.90
1,031.60
722.50
635.30
542.40
452.70
376.60
398.40
378.30
413.70
Sundry Debtors
1,223.70
1,291.80
1,063.90
883.20
714.50
770.50
599.80
509.70
491.70
495.80
Cash & Bank
998.60
1,057.20
1,322.80
1,044.30
1,538.60
937.50
804.40
672.90
523.30
441.50
Other Current Assets
809.20
525.50
373.30
395.80
300.70
171.60
157.60
136.90
114.30
56.70
Short Term Loans & Adv.
265.60
153.10
54.70
24.10
227.10
75.80
81.80
81.40
37.10
20.20
Net Current Assets
1,317.00
1,850.00
2,007.30
2,369.40
2,305.20
1,007.90
1,259.20
1,250.10
983.90
746.60
Total Assets
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
1,283.10
1,154.60
662.10
640.00
370.60
210.70
560.70
471.20
564.10
798.50
PBT
870.90
1,002.60
610.00
849.70
751.30
624.10
537.70
610.20
395.20
447.10
Adjustment
921.40
472.60
355.70
204.40
42.00
74.00
134.00
147.30
144.80
163.50
Changes in Working Capital
-165.10
-29.10
-106.50
-211.10
-176.20
-354.00
37.70
-192.30
98.00
269.20
Cash after chg. in Working capital
1,627.20
1,446.10
859.20
843.00
617.10
344.10
709.40
565.20
638.00
879.80
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-344.10
-291.50
-197.10
-203.00
-246.50
-133.40
-148.70
-94.00
-73.90
-81.30
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,558.90
-713.80
-684.00
-498.50
-1,141.70
-508.70
-938.10
-375.80
-359.50
-314.50
Net Fixed Assets
744.40
-280.60
-177.90
-215.90
-216.90
-57.90
-322.80
-213.80
-75.20
-134.97
Net Investments
-890.30
107.80
-310.70
-79.30
-3,688.10
328.50
125.80
38.00
-171.10
-67.26
Others
-1,413.00
-541.00
-195.40
-203.30
2,763.30
-779.30
-741.10
-200.00
-113.20
-112.27
Cash from Financing Activity
387.60
-241.70
-239.70
-177.50
1,067.60
186.20
426.00
-8.60
-186.30
-274.60
Net Cash Inflow / Outflow
111.80
199.10
-261.60
-36.00
296.50
-111.80
48.60
86.80
18.30
209.40
Opening Cash & Equivalents
659.30
449.00
710.20
757.50
457.50
557.00
474.00
369.00
359.00
139.90
Closing Cash & Equivalent
824.70
659.30
449.00
710.20
757.50
462.60
557.00
474.00
369.00
359.00

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
54.97
50.17
42.59
39.74
33.61
26.93
24.21
21.59
18.16
16.25
ROA
6.94%
9.25%
4.55%
7.64%
7.96%
8.72%
8.47%
12.28%
9.10%
11.50%
ROE
14.26%
18.00%
8.74%
15.26%
16.17%
17.22%
15.68%
21.50%
16.59%
20.58%
ROCE
14.35%
16.11%
8.92%
12.59%
13.93%
15.30%
15.75%
22.47%
16.74%
20.33%
Fixed Asset Turnover
0.78
0.85
0.73
0.89
1.05
1.09
1.12
1.11
1.06
0.97
Receivable days
72.10
77.96
86.05
74.35
80.16
80.09
69.48
72.22
84.37
93.20
Inventory Days
70.72
58.05
60.00
54.81
53.71
48.47
48.54
56.01
67.67
77.71
Payable days
80.65
81.98
87.98
78.68
71.28
58.15
55.73
65.24
70.25
70.62
Cash Conversion Cycle
62.18
54.04
58.07
50.48
62.59
70.42
62.29
62.99
81.79
100.29
Total Debt/Equity
0.40
0.40
0.44
0.48
0.61
0.35
0.30
0.10
0.12
0.17
Interest Cover
19.72
18.12
10.57
33.05
25.90
71.12
317.29
76.33
33.13
19.40

Annual Reports:


News Update


  • Biocon’s arm receives Rs 555 crore capital injection from ADQ
    8th Jan 2021, 09:08 AM

    Post the completion of this transaction, Biocon will hold 89.89% stake in Biocon Biologics on a fully diluted basis

    Read More
  • Biocon launches Tacrolimus capsules in US
    28th Dec 2020, 16:51 PM

    The launch of Tacrolimus capsules in the US is another milestone for Biocon that reflects commitment to continually evaluate and expand portfolio of complex products to serve patients

    Read More
  • Biocon’s arm signs MoU with CSSC for Mission 10 cents
    16th Dec 2020, 08:52 AM

    Tanzania will be the first country in Africa that will benefit from this collaboration between Biocon Biologics and CSSC

    Read More
  • Biocon’s arm raises Rs 1125 crore through OCDs
    10th Dec 2020, 11:22 AM

    The company has allotted 1,125 OCDs having face value of Rs 1 crore each

    Read More
  • Biocon enters into agreement to acquire stake in HRTPL
    23rd Nov 2020, 15:55 PM

    HRTPL was incorporated on September 25, 2020, which will engage in the business of power generation

    Read More
  • Biocon’s arm receives Rs 1,125 crore capital injection from Goldman Sachs
    9th Nov 2020, 08:52 AM

    Goldman Sachs will be issued Optionally Convertible Debentures at a post money equity valuation of $3.94 billion

    Read More
  • Biocon ranked among top 5 biotech employers globally
    30th Oct 2020, 12:17 PM

    Ranked at No. 5 among global pharma and biotech companies in 2020, Biocon has moved up steadily from No. 7 in 2018 and No. 6 in 2019

    Read More
  • Biocon reports 23% fall in Q2 consolidated net profit
    23rd Oct 2020, 10:32 AM

    Total income of the company increased by 9.63% at Rs 1760.30 crore for Q2FY21

    Read More
  • Biocon - Quarterly Results
    22nd Oct 2020, 23:53 PM

    Read More
  • Biocon’s CSR arm signs MoU with BMRCL
    9th Oct 2020, 09:58 AM

    MoU aims to contribute Rs 65 crore towards funding the construction of the proposed Hebbagodi Metro Station on Hosur Road

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.